CompletedNot Applicable

Pro-active Fecal Calprotectin Monitoring PROMOTE-UC

Canada726 participantsStarted 2018-12-01

Plain-language summary

Hypothesis: Pro-active home fecal calprotectin testing in patients with Ulcerative Colitis will allow early detection and treatment of inflammation to prevent symptomatic flares. This will result in less steroid use, fewer hospitalizations and a reduced risk of surgery, as well as improved quality of life and adherence to medication.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients age 19 years or older with Ulcerative Colitis * Symptomatic remission defined as a modified Partial Mayo score ≤ 2 with a rectal bleeding score = 0 * Able to use IBDocTM test kit which requires a smart phone with a camera and internet access to download the CalApp® which interprets the measurement * Able to give informed consent to the study protocol Exclusion Criteria: * Patients experiencing a symptomatic flare * Patients currently receiving therapy as part of a clinical trial * Pregnancy

What they're measuring

The time to a symptomatic flare, defined as an increase in modified partial Mayo score > 2 points from baseline or a rectal bleeding score > 1

Timeframe: 6 months

Trial details

NCT IDNCT03549988

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-30

View on ClinicalTrials.gov More Ulcerative Colitis trials